Trial Selection Rising

RET fusion

melanoma · Therapy Not Normalized

RET fusion is flagged as trial selection rising because public trials show inclusion required evidence in 7 contexts. FDA CDx context should be reviewed manually.

Role evidence

Usage summary

Strongest role: Inclusion Required

Inclusion-required count: 5

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 2

Common snippets: BRAF V600E | BRAF V600E

Threshold label: Moderate

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Not Found

CDx maturity score: 1/5

Confidence: Medium

Patent-density signal

Diagnostic appendix

Signal count: 0

Recent signals: 0

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT01642342 | https://clinicaltrials.gov/study/NCT01136967 | https://clinicaltrials.gov/study/NCT01303341 | https://clinicaltrials.gov/study/NCT01950390 | https://clinicaltrials.gov/study/NCT07686367 | https://clinicaltrials.gov/study/NCT00729807 | https://clinicaltrials.gov/study/NCT02587650